Charles River Laboratoriesvs.IQVIA Holdings
CRL vs IQV · both in CDMO & pharma manufacturing, part of the Medicine, pharma & life science value chain: Contract development and manufacturing of medicines, the industrial backbone behind the drugs.
IQVIA Holdings is about 3.1× larger than Charles River Laboratories by market cap; year to date, Charles River Laboratories leads (+50.5% vs +14.5%).
Side by side
| CRL | IQV | |
|---|---|---|
| Market cap | $13.8B | $42.2B |
| Price | $298.00 | $258.88 |
| Today | −0.8% | +0.3% |
| Return YTD | +50.5% | +14.5% |
| Return 1Y | +76.5% | +28.5% |
| Since June 26, 2026 | +38.1% | +35.4% |
| P/E | — | 30.7 |
| P/S | 3.5 | 2.5 |
| P/B | 4.9 | 6.8 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Charles River LaboratoriesCRL
Preclinical work that drug and biotech companies choose not to do in-house: research models, safety testing, laboratory services through development, and support for cell and gene therapy.
Full CRL profile →IQVIA HoldingsIQV
Drug companies outsource clinical trials to IQVIA, and many of the same customers buy its health data and analytics. A third arm sells commercial services to the pharmaceutical industry.
Full IQV profile →More CRL & IQV comparisons
Other head-to-heads in the CDMO & pharma manufacturing segment.